Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy.
Saved in:
| Title: | Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy. |
|---|---|
| Authors: | Colbert GB; Division of Nephrology, Texas A&M University College of Medicine at Dallas, Dallas, TX, USA., Madariaga HM; Department of Surgery, Abdominal Transplant Institute, Tufts Medical Center, Boston, MA, USA., Gaddy A; Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Elrggal ME; Division of Nephrology, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia., Lerma EV; Section of Nephrology, University of Illinois at Chicago, Chicago, IL, USA.; Division of Nephrology, Associates in Nephrology, Chicago, IL, USA. |
| Source: | Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2025 Jul; Vol. 18 (7), pp. 441-448. Date of Electronic Publication: 2025 Jul 16. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101278296 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1751-2441 (Electronic) Linking ISSN: 17512433 NLM ISO Abbreviation: Expert Rev Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
